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Introduction 
Acute Lymphoblastic Leukemia (ALL) is a neoplasm of immature lymphoid progenitors, characterized by clonal 
expansion of leukemic cells in the bone marrow (BM). It can affect both children and adults, but is more prevalent 
between ages of 2 and 5 years. The majority of ALL cases are aneuploidy or harbor recurring structural chromosomal 
rearrangements that are important in initiating events in leukemogenesis and which subdivides between the subtypes 
B and T, but that are insufficient to explain the biology and heterogeneity of ALL. For that reason it is necessary a 
thorough study about genetics of the disease.  
Methods and objectives 
Bibliographic search of reviews and original articles in 
databases such as PubMed (NCBI) has been made in order to 
accomplish the following goals: present the current situation of 
the disease and how the genetic study has allowed us to 
understand the disease as well as the risk stratification, and 
develop new therapies. 
Morphology 
Immunophenotype 
Genetic 
analysis 
•  ALL-L1 
•  ALL-L2 
•  ALL-L3 
	   •  ALL-B: CD19, CD20, CD22, CD24,  
    CD79a, CD10, cIgM and mIgM 
•  ALL-T: CD2, CD3, CD5, CD1a, CD4 
     and CD7  
	  •  Conventional cytogenetics 
•  Molecular cytogenetics 
•  PCR and CGH 
	  
Clinical diagnostic 
1992 Comparative 
genomic 
hybridation (CGH) 
was developed 
1985 Invention of polymerase chain 
reaction (PCR) 
1982 Fluorescence in situ hybridation 
was developed 
1956 The human 
chromosome 
number is 46 
Development of 
conventional 
cytogenetics  
Techniques 
Cytogenetic 
alterations 
Genetic lesion  Associated clinical features and 
specifics treatments 
Prognosis  
Changes in 
chromosomal 
Hyperdiploidy 
(>50) 
20% with FLT3 activation Good prognosis  
Number 25% Hypodiploidy 
(<44) 
High frequency of RAS pathway and 
IKAROS gene family mutations 
Poor prognosis  
Structural B-ALL   
abnormalities 
chromosome 
50% 
 
BCR-ABL t(9;22) Associated with IKZF1 or CDKN24 
deletions. Treatment with tyrosine 
kinase inhibitors like imatinib but 
resistance develops rapidly. BCR-ABL1-
like with deletions in IKZF, 
rearrangements in CRLF2 and JAK 
mutations.  
Poor prognosis  
MLL 
rearrangements 
Unregulated FLT3. Use of cytarabine for 
some rearrangements. Treatment with 
FLT3 inhibitors like sorafenib or 
crenalanib. 
Improved outcome  
ETV6-RUNX1 
t(12;21) 
Intensive chemotherapy that includes 
asparaginase. Sometimes present 
iAMP21with multiple copies of RUNX1.  
Current development of treatment in the 
UK 
Good prognosis  
E2A-PBX1 t(1;19) Increased incidence in African 
Americans. Intensified chemotherapy 
Generally excellent 
prognosis  
T-ALL   
NOTCH1 t(7;9) Resistant tumours, gain of function that 
activates MYC 
HOX 
rearrangements 
Elevated expression; HOX11 inhibition 
of PP2A and PP1 phosphatases 
HOX11 T-ALL has better 
prognosis than other T-
ALL molecular  
TAL1/SCL t(1;14) Dimerize E2A and HEB transcription 
factors, blocking T cell differentiation 
Good and poor outcomes  
LYL1 t(7;19) Dimerize E2A and HEB transcription 
factors, blocking T cell differentiation 
Cytogenetic technologies permit the detection of different types of chromosomal and 
genetic abnormalities. There are three types of chromosomal aberrations: those 
involving changes in chromosome number, those with structural abnormalities and 
those that present a normal karyotype. The genetics of these chromosomal alterations 
allow us to know the incidence and prevalence of each one, use it for monitoring the 
disease, learn about the biology of the disease, the risk stratification and the potential 
markers for therapy. Hyperdiploidy, with gain of at least 5 chromosomes, is one of 
the most frequent alterations in childhood, and is associated with a favourable 
outcome. Hyperdiploidy includes quasitri/tetraploidy. However, hypodiploidy with 
fewer than 44 chromosomes is associated with poor prognosis. The recurring 
chromosomal rearrangements differentiate, B-ALL or T-ALL and the new 
rearrangements are critical for leukemogenesis and commonly perturb genes encoding 
regulators of haematopoiesis, tumour suppressors, oncogenes or tyrosine kinases, but 
in most cases they are primary events that need others to produce disease. Moreover, 
some patients present a normal karyotype (diploid), which has an improved 
outcome.  
GENETIC ALTERATIONS 
Early T cell 
precursor 
PAX5 
JAK1/2 
CRLF2 
Personalized medicine 
There is no consensus on what 
constitutes an optimal treatment  
Develop less toxic treatments while 
preserving earlier gains in efficacy 
Studies have begun to identify a number of 
polymorphisms, such as ARID5B, IKZF1, CEBPE 
and CDKN2A 
New epigenetic studies 
Novel alteration Novel perspectives Conclusion 
ALL is the most common and heterogeneous neoplasm in childhood and its also 
affects adults. Early diagnosis is important to perform a good treatment and get 
complete remission. 
Genetics have allowed us to identify a large number of chromosomal alterations 
that are associated with biological features. The genetics alterations has been used 
to define B-ALL and T-ALL, prognostic and risk stratification. 
Conventional cytogenetic analysis should be a mandatory routine examination. 
Further genetic study must be carried out to understand the disease and create 
specialized treatments. 
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Figure 3 and 4: Hyperdiploidy (3) and Hypodiploidy karyotype from Quintero M, Rojas-Atencii A, Ruiz A, González M, Herrera J, Atencio F, Delgado W, Urdaneta K, Pérez 
F, 2003. Anomalías cromosómicas en pacientes venezolanos con mieloma múltiple. Scielo. Vol. 44 
Figure 5: Chromosomal translocation BCR-ABL from Leucemia	  linfoblás6ca	  aguda	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  Nacional	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  p.	  1-­‐71	  
Figure 6: iAMP21. A) Partial G-banded karyotypes showing pairs of chromosomes 21 from six patients. In each pair the normal chromosome 21 is on the left and the 
abnormal homologue is on the right. B) G-banding and mBAND partial karyotypes of normal left and abnormal right chromosomes 21 from iAMP21 from Harrison	  C.J,	  2009.	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Figure 1: Bone marrow aspiration and biopsy from National 
Cancer Institute <http://www.cancer.gov> [26/05/2015] 
 
Figure 2: Human male Karyotype after 
hybridization with of a seven-fluorochrome M-
F I S H m i x f r o m N a t u r e l p r o t o c o l s 
<www.nature.com> [26/05/2015] 
